Who makes ACI-24.060 at Dose C?

ACI-24.060 at Dose C is developed by AC Immune SA.

What development phase is ACI-24.060 at Dose C in?

ACI-24.060 at Dose C is in Phase 1.

Last reviewed 2026-05-15 · How we verify

ACI-24.060 at Dose C

AC Immune SA · Phase 1 active Biologic

At a glance

Generic name	ACI-24.060 at Dose C
Sponsor	AC Immune SA
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study) (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ACI-24.060 at Dose C CI brief — competitive landscape report
ACI-24.060 at Dose C updates RSS · CI watch RSS
AC Immune SA portfolio CI